Skip to main content
. 2017 Jul 17;8(47):82217–82230. doi: 10.18632/oncotarget.19283

Figure 4. Cox-2 regulates stem-ness in GSCs.

Figure 4

(A) Coxinhibition with indomethacin or Cox-2 inhibition with celecoxib (50 μM) or siRNA-COX2 in GliNS1 GSCs results in decreased expression of the stem-ness marker, Sox2, and increased expression of the differentiation markers, GFAP and β-tubulin. (B) Treatment with iloprost (100 μM) results in increased expression of the stem-ness marker, Sox2, and decreased expression of the differentiation markers, GFAP and β-tubulin, in GSCs (2012016, 2012018, 201431, 2014046, 2014057), and the U87 glioblastoma cell line. * p <0.01, **p < 0.05. (C) Cox-2 expression in the GSC line GliNS1 following forced GSC differentiation by withdrawal of growth factors and treatment with serum. (D-F) Coxinhibition with indomethacin or Cox-2 inhibition with celecoxib (50 μM) or siRNA-COX2 results in decreased self-renewal in GliNS1 GSCs, as measured by the sphere formation assay. (G) Treatment of GliNS1 GSCs with iloprost (100 μM) results in increased GSC self-renewal, as measured by sphere formation. Data are represented as mean ± SEM.